Last reviewed · How we verify
IBI356 for MAD
At a glance
| Generic name | IBI356 for MAD |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI356 for MAD CI brief — competitive landscape report
- IBI356 for MAD updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI